RxDoctor Payments Data

Molly Nicastro, PA

Medical · Doylestown, PANPI 1639689540

Payments from drug & device makers

$3,324in general payments, 2019–2025

Across 161 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$731
  • AbbVie$600
  • GSK$273
  • Lilly USA, LLC$196
  • Pfizer$195
  • Biohaven Pharmaceuticals, Inc.$164
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,324 in reported general payments places this provider in the 85th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$39,869
Medicare patients
207
Services billed
625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$37,680
JardianceEmpagliflozin15$24,609
LinzessLinaclotide11$9,702
Atorvastatin Calcium223$2,815
Duloxetine Hcl16$1,957
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$1,375
Lisinopril135$1,348
Metoprolol Succinate70$1,298
SynthroidLevothyroxine Sodium33$1,263
Amlodipine Besylate137$1,059
Losartan Potassium77$833
Metformin Hcl78$749
Bupropion XlBupropion Hcl15$716
Famotidine26$695
Levothyroxine Sodium80$664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$731$37,68020 claims
Boehringer IngelheimJardiance$18$24,60915 claims
AbbVieLinzess, Synthroid$600$10,96544 claims
Almatica Pharma LLCSertraline Hcl$18$40251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →